FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807737802> ?p ?o ?g. }

• W2807737802 endingPage "711" @default.
• W2807737802 startingPage "703" @default.
• W2807737802 abstract "Biliary tract cancer, carcinoma of the extrahepatic bile ducts, carcinoma of the gall bladder, ampullary carcinoma and intrahepatic cholangiocarcinoma are often identified at an advanced stage and have poor prognoses. Although effective chemotherapy regimens are needed, their development remains unsatisfactory. From the results of a phase III clinical trial (ABC-02 trial), gemcitabine plus cisplatin is the standard first-line chemotherapeutic regimen for advanced biliary tract cancer. A phase III trial of gemcitabine plus cisplatin vs. gemcitabine plus S-1 therapy (FUGA-BT) demonstrated the non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin. A phase III trial of gemcitabine plus cisplatin vs. gemcitabine plus cisplatin plus S-1 (MITSUBA) was conducted, and the report on the results of the final analysis is being awaited. A standard second-line chemotherapeutic regimen has not yet been established. Fluoropyrimidines are frequently used in clinical practice. Despite many clinical trials being conducted with molecular targeted agents including erlotinib, cetuximab, panitumumab, bevacizumab, sorafenib, cediranib, trametinib and vandetanib, no agent has shown to be effective for advanced biliary tract cancer. Next-generation sequencing shows great promise by allowing rapid mutational analysis of multiple genes in human cancers, and attractive driver genetic alterations have been reported in biliary tract cancer. FGFR2 fusion gene, mutations of IDH1/2, BRAF, BRCA1/2, ATM, PIK3CA and overexpression of c-MET and HER2/neu are reported relatively frequently and are interesting targets. Therefore, future development in precision medicine utilizing next-generation sequencing is expected. Although the efficacy of immune checkpoint inhibitors, such as anti-PD-1, anti-PD-L1 and anti-CTLA4 antibodies, remains unknown at present, basic data and results of ongoing clinical trials are anticipated." @default.
• W2807737802 created "2018-06-21" @default.
• W2807737802 creator A5005262911 @default.
• W2807737802 creator A5022537134 @default.
• W2807737802 creator A5050530209 @default.
• W2807737802 creator A5056197140 @default.
• W2807737802 creator A5057311746 @default.
• W2807737802 creator A5076696174 @default.
• W2807737802 date "2018-06-11" @default.
• W2807737802 modified "2023-10-17" @default.
• W2807737802 title "New developments in systemic therapy for advanced biliary tract cancer" @default.
• W2807737802 cites W1806572515 @default.
• W2807737802 cites W1891752511 @default.
• W2807737802 cites W1903979702 @default.
• W2807737802 cites W1963537359 @default.
• W2807737802 cites W1974564771 @default.
• W2807737802 cites W1979379023 @default.
• W2807737802 cites W1983872049 @default.
• W2807737802 cites W1989145928 @default.
• W2807737802 cites W1994746695 @default.
• W2807737802 cites W1996138775 @default.
• W2807737802 cites W2007555374 @default.
• W2807737802 cites W2012887353 @default.
• W2807737802 cites W2015613033 @default.
• W2807737802 cites W2018041848 @default.
• W2807737802 cites W2019438357 @default.
• W2807737802 cites W2050249255 @default.
• W2807737802 cites W2052205828 @default.
• W2807737802 cites W2063209335 @default.
• W2807737802 cites W2063276992 @default.
• W2807737802 cites W2063432158 @default.
• W2807737802 cites W2063515380 @default.
• W2807737802 cites W2068110847 @default.
• W2807737802 cites W2071125719 @default.
• W2807737802 cites W2072564984 @default.
• W2807737802 cites W2073597876 @default.
• W2807737802 cites W2081994793 @default.
• W2807737802 cites W2087336559 @default.
• W2807737802 cites W2096796171 @default.
• W2807737802 cites W2097924418 @default.
• W2807737802 cites W2097995306 @default.
• W2807737802 cites W2102539343 @default.
• W2807737802 cites W2103198051 @default.
• W2807737802 cites W2104347254 @default.
• W2807737802 cites W2108756633 @default.
• W2807737802 cites W2113222623 @default.
• W2807737802 cites W2114327118 @default.
• W2807737802 cites W2115261608 @default.
• W2807737802 cites W2118520585 @default.
• W2807737802 cites W2126983598 @default.
• W2807737802 cites W2132215313 @default.
• W2807737802 cites W2135849593 @default.
• W2807737802 cites W2136264959 @default.
• W2807737802 cites W2136629154 @default.
• W2807737802 cites W2137875447 @default.
• W2807737802 cites W2141042450 @default.
• W2807737802 cites W2145857211 @default.
• W2807737802 cites W2157232767 @default.
• W2807737802 cites W2159243852 @default.
• W2807737802 cites W2162445014 @default.
• W2807737802 cites W2166662937 @default.
• W2807737802 cites W2168106806 @default.
• W2807737802 cites W2171559250 @default.
• W2807737802 cites W2236095593 @default.
• W2807737802 cites W2254163334 @default.
• W2807737802 cites W2263310282 @default.
• W2807737802 cites W2271127196 @default.
• W2807737802 cites W2470260050 @default.
• W2807737802 cites W2471392110 @default.
• W2807737802 cites W2508622625 @default.
• W2807737802 cites W2520639290 @default.
• W2807737802 cites W2568666199 @default.
• W2807737802 cites W2589049990 @default.
• W2807737802 cites W2597802455 @default.
• W2807737802 cites W2598654945 @default.
• W2807737802 cites W2600753121 @default.
• W2807737802 cites W2602761127 @default.
• W2807737802 cites W2603694770 @default.
• W2807737802 cites W2635951006 @default.
• W2807737802 cites W2754539013 @default.
• W2807737802 cites W2758325187 @default.
• W2807737802 cites W2764091758 @default.
• W2807737802 cites W2767305368 @default.
• W2807737802 cites W2769909737 @default.
• W2807737802 cites W2884793792 @default.
• W2807737802 cites W2886807331 @default.
• W2807737802 doi "https://doi.org/10.1093/jjco/hyy082" @default.
• W2807737802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29893894" @default.
• W2807737802 hasPublicationYear "2018" @default.
• W2807737802 type Work @default.
• W2807737802 sameAs 2807737802 @default.
• W2807737802 citedByCount "49" @default.
• W2807737802 countsByYear W28077378022018 @default.
• W2807737802 countsByYear W28077378022019 @default.
• W2807737802 countsByYear W28077378022020 @default.
• W2807737802 countsByYear W28077378022021 @default.
• W2807737802 countsByYear W28077378022022 @default.
• W2807737802 countsByYear W28077378022023 @default.

• next